E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Participants in this study have type 1 diabetes which is defined as lack of own insulin production |
Type 1 diabetes er en kronisk sygdom som er karakteriseret ved at man ikke kan producere insulin til at få blodglukose ned. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045228 |
E.1.2 | Term | Type I diabetes mellitus |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the CGM-derived time in range (3.9-10.0 mmol/l) during the last two weeks of the 16-week interventions with Fiasp versus NovoRapid |
|
E.2.2 | Secondary objectives of the trial |
To compare insulin pump settings when pumps are optimally adjusted to each of the two insulin types. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Age ≥ 18 years Type 1 diabetes for ≥ 5 years HbA1c 53-75 mmol/mol (7.0-9.0%) Insulin pump treatment for ≥ 6 months (all insulin pump makes except hybrid closed-loop systems are eligible for inclusion) CGM use for ≥ 6 months (all CGM makes are eligible for inclusion) Carbohydrate counting for all snacks and meals Use of the insulin pump bolus calculator for all meals and snacks |
|
E.4 | Principal exclusion criteria |
Breast-feeding, pregnant, planning to become pregnant or of child-bearing potential and not using adequate contraceptive methods Gastroparesis (clinical assessment) Shift work Changing insulin needs throughout the menstrual cycle that requires different basal rate patterns Use of a hybrid closed-loop system Use of flash glucose monitoring Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start Chronic paracetamol use Alcohol or drug abuse Severe cardiac disease or retinopathy contraindicating HbA1c below 53 mmol/mol Impaired renal function (eGFR< 60 ml/min/1.73 m2) History of local skin reactions to Fiasp and/or Iasp Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation Lack of compliance with key study procedures at the discretion of the investigator Unacceptable adverse events at the discretion of the investigator Less than 40 weeks guarantee remaining on insulin pump |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Difference in CGM-derived time in range (3.9-10.0 mmol/l) during the interventions with Fiasp versus Novorapid |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During the last two weeks of each 16-week interventions |
|
E.5.2 | Secondary end point(s) |
The following endpoints are assessed by CGM values downloads from the last two weeks of the 16-week treatment periods Difference between treatments in mean glucose Difference between treatments in coefficient of variation Difference between treatments in standard deviation Difference between treatments in percentage of time < 3.9 mmol/l Difference between treatments in percentage of time < 3.0 mmol/l Difference between treatments in percentage of time >10 mmol/l Difference between treatments in percentage of time > 13.9 mmol/l Difference between treatments in low blood glucose index Difference between treatments in high blood glucose index Difference between treatments in eHbA1c
The following eight endpoints are based on insulin pump downloads from the last two weeks of the 16-week treatment periods Difference between treatments in total insulin dose# Difference between treatments in total basal insulin# Difference between treatments in total bolus insulin# Difference between treatments in basal/bolus-ratio# Difference between treatments in weighted ICRs* Difference between treatments in weighted ISF* Difference between treatments in mean number of boluses per day
Difference between treatments in relation between daily carbohydrate intake and time in range
Difference in change in fructosamine, cholesterol, HDL, LDL, triglycerides, sodium, potassium, creatinine, u-alb-crea ratio and TSH Difference in number of severe hypoglycemia events (cognitive impairment requiring external assistance for recovery) Difference in number of diabetic ketoacidosis events Difference in number of AEs Compliance with instruction to change insulin infusion set every 2nd day |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
# indicates that the outcome will be calculated for the following time intervals: 12 AM – 12AM, 6 AM – 12 AM (wake), and 12 AM – 6 AM (sleep) * indicates that the outcome will be calculated for the following time intervals: 12 AM – 6 AM, 6 AM – 11 AM, 11 AM – 4 PM, 4 PM – 12 AM |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 18 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 18 |